Entheon Biomedical

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
Sponsored
Entheon Acquires Pre-Testing Genetics Platform For Psychedelic Treatment
Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
Sponsored
Entheon Acquires Pre-Testing Genetics Platform For Psychedelic Treatment
Entheon Biomedical And Psygen Labs Inc.'s DMT Drug Supply Agreement
Psyched: Canada Allows Psilocybin Use For Healthcare Pros, UK Begins DMT Trials, Cybin To Purchase Adelia

Entheon Biomedical Recent News

Research Efforts From Entheon Biomedical Suggest Psychedelics' Potential In Treating Chronic Addictions
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
Why Are Psychedelics And Mining Companies Merging In Canada?
Since the first psychedelic companies went public in March, an array of other psychedelic start-ups followed along in a trend that can now be safely referred to as the "Psychedelic Rush."
Entheon Biomedical CEO Timothy Ko On The Potential Of Psychedelics In Addiction Treatment
Among the biggest challenges faced by the psychedelics industry is the stigma that surrounds it. "The anti-drug marketing of the past decades was highly effective, and so now when psychedelics are mentioned, visions of tie-dye come to mind," Timothy Ko told Benzinga.  The times are changing.